Brief: Sana Biotechnology Announces FDA Nod For Human Clinical Trials For Car T Therapy For B-Cell Malignancies

Sana Biotechnology

26/01/2023 22:29

Jan 26 (Reuters) - Sana Biotechnology Inc  SANA.O :
    * SANA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR SC291, A HYPOIMMUNE-MODIFIED,
CD19-TARGETED ALLOGENEIC CAR T THERAPY FOR PATIENTS WITH B-CELL
MALIGNANCIES
    * SANA BIOTECHNOLOGY INC - GOAL IS TO REPORT INITIAL SC291
CLINICAL DATA THIS YEAR
    * SANA BIOTECHNOLOGY INC - GOAL IS TO SUBMIT A SECOND IND
FROM
PLATFORM THIS YEAR FOR SC262

Source text for Eikon:  ID:nGNX6BsSXN 
Further company coverage:  SANA.O 
 ((Reuters.Briefs@thomsonreuters.com;))